Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action

• Այլ հեղինակներ: Allison, Simon J (Խմբագիր)
• Ձևաչափ: Էլեկտրոնային Գրքի գլուխ
• Լեզու: անգլերեն
• Հրապարակվել է: MDPI - Multidisciplinary Digital Publishing Institute 2022
• Խորագրեր: Technology: general issues; History of engineering & technology; microtubule acetylation; triple-negative breast cancer; anti-cancer agent; apoptosis; K562; 8-hydroxydaidzein; autophagy; BCR-ABL; MAPK; NF-κB; c-myc; RNA interference; siRNA; oncogene; gene silencing; expression; nanosystems; Cytochrome P450; CYP1A1; CYP1B1; CYP2W1; breast cancer; prodrug; bioprecursor; duocarmycin; phortress; AQ4N; 5-FU resistance; colorectal cancer; drug repurposing; Genomics of Drug Sensitivity in Cancer; Connectivity Map; anticancer drug; B-lactam steroid alkylators; synthetic lethality; poly (ADP-ribose) polymerase inhibitors; ovarian cancer; hybrid steroidal alkylating agents; migration; invasion; glioblastoma; CCN1; mesenchymal-amoeboid transition; biomarker; HepG2; Huh7; isatin sulfonamides; angiogenesis; cancer hallmarks; molecular docking; EGFR tyrosine kinase inhibitor; photon upconversion; triplet-triplet annihilation; in vivo imaging; PLGA; nanoparticles; affibody molecule; human epidermal growth factor receptor 3 (HER3); BxPC-3; emtansine; DM1; albumin binding domain; affibody drug conjugate (AffiDC); n/a
• Առցանց հասանելիություն: DOAB: download the publication; DOAB: description of the publication

Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established....